Palliative Outcome Evaluation Muenster I (POEM I)
Assessment of Palliative Care in Inpatient and Outpatient Settings Using the Integrated Palliative Care Outcome Scale: a Multi-centric Observational Study
For patients with an advanced disease and their families an excellent and compassionate care is essential. However, in hospitals optimal end-of-life care is not yet fully realized and patient's needs are often not met. Palliative care is able to increase patients' quality of life and to carefully meet their and their families' needs.
To improve the awareness of unmet needs patient-reported outcome measurement has been the pivot of latest palliative care research. Besides the improvement of care outcome measurement allows the evaluation of the quality of palliative care and comparisons on a national and international level.
The aim of the present study is to evaluate the quality of palliative care in different settings (palliative care unit, inpatient and outpatient consultation teams) using the Integrated Palliative Care Outcome Scale (IPOS). The IPOS has been lately developed as improved follow-up version of the Palliative Care Outcome Scale (POS) integrating most important questions and simultaneously being brief and comprehensive. The study is planned as a multi-centric observational study. Primary endpoint is the reduction of symptom burden of patients.
The clinical study hypothesis bases on the assumption that palliative care can change the symptom burden, measured by a change in the IPOS overall profile score, and that there might be a difference in the size of the effect depending on the caring setting.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
After the enrolment and consent of participation the patient receive a questionnaire consisting of three independent assessments: To assess the symptom burden and specific palliative care needs the Integrated Palliative Outcome Scale (IPOS) is used. To measure the generic health-related quality of life the patient has to answer the EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L). To get an opinion of the general condition the patient is to complete the NCCN Distress Thermometer which includes a visual analogue scale (with values from 0 to 10).
Meanwhile, a professional palliative caregiver completes a questionnaire about the main demographic aspects of the patients and assess the palliative care needs and the symptom burden using the IPOS.
After one week both, patient and professional palliative caregiver, will receive the same questionnaires again to assess the change from baseline.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Philipp Lenz, PD Dr. med.
- Phone Number: +49 (0)251 8353052
- Email: philipp.lenz@ukmuenster.de
Study Locations
-
-
North Rhine-Westphalia
-
Muenster, North Rhine-Westphalia, Germany, 48143
- Not yet recruiting
- Hospital St. Raphael Muenster
-
Contact:
- Marc Theisen, Dr. med.
- Phone Number: +49 (0)251 5007 4118
- Email: m.theisen@alexianer.de
-
Muenster, North Rhine-Westphalia, Germany, 48145
- Not yet recruiting
- Hospital St. Franziskus Muenster
-
Contact:
- Anne Bremer, Dr. med.
- Phone Number: +49 (0)251 935 5564
- Email: onkologie@sfh-muenster.de
-
Muenster, North Rhine-Westphalia, Germany, 48149
- Recruiting
- University hospital Muenster
-
Contact:
- Philipp Lenz, PD Dr. med.
- Phone Number: +49 (0)251 8353052
- Email: philipp.lenz@ukmuenster.de
-
Muenster, North Rhine-Westphalia, Germany, 48161
- Recruiting
- Palliativnetz Muenster
-
Contact:
- Ulrike Hofmeister, Dr. med.
- Phone Number: +49 (0)251 1625662
- Email: info@palliativnetz-muenster.de
-
Warendorf, North Rhine-Westphalia, Germany, 48231
- Not yet recruiting
- Hospital St. Josef Warendorf
-
Contact:
- Dirk Domagk, Prof. Dr. med.
- Phone Number: +49 (0)2581 20 1752
- Email: palliativstation@jhwaf.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Indication for palliative care due to any advanced life-limiting and progressive disease
- 18 years and older
Exclusion Criteria:
- Age under 18 years
- pregnant or breastfeeding women
- Inability to understand information for participation
- Refusal of participation
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PCU (unit)
Those patients who received specialised palliative care on a palliative care unit.(palliative
care unit)
|
specialized palliative care provided in different settings
|
|
IPCC (hospital)
Those patients admitted to a regular hospital ward who received specialised palliative care from an inpatient palliative care consultation team. (inpatient palliative care consultation team) |
specialized palliative care provided in different settings
|
|
OPCC (outpatient)
Those patients who received specialised palliative care at home from an outpatient palliative care consultation team.
(outpatient palliative care consultation team)
|
specialized palliative care provided in different settings
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
symptom burden (IPOS)
Time Frame: From Baseline to End of Follow-Up (0, 1 week)
|
Change from baseline in palliative care needs and specific symptoms (at day 7) assessed with the Integrated Palliative Care Outcome Scale (IPOS).
The IPOS includes 10 symptoms and 7 questions on patients and carers emotional situation, spiritual concerns, and provision of information and support.
The overall profile score is the sum of the scores from each of the 17 questions.
|
From Baseline to End of Follow-Up (0, 1 week)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Generic health-related quality of life (EQ-5D-5L)
Time Frame: From Baseline to End of Follow-Up (0, 1 week)
|
Change from baseline in patients' generic health-related quality of life measured with the EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L).
The EQ-5D-5L essentially consists of 2 pages - the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The descriptive system comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression).
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.
The visual analogue scale of the EQ-5D-5L questionnaire ranges from 0 to 100 (with 0 representing the worst health the patient can imagine and 100 representing the best health the patient can imagine).
|
From Baseline to End of Follow-Up (0, 1 week)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UKM_POEM I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
NCT05693831RecruitingCancer | Relapsed Cancer | Refractory Cancer
-
NCT02045381CompletedCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer Pelvis
-
NCT07196241RecruitingCancer | Adolescent Cancer | Young Adult Cancer
-
NCT02511821CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer
-
NCT04310345CompletedAdvanced Cancer | Relapsed Cancer | Refractory Cancer
-
NCT04044430TerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer
-
NCT05259696CompletedMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer
-
NCT07224204RecruitingCancer | Adolescent Cancer | Young Adult Cancer
-
NCT03146039WithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III
Clinical Trials on specialized palliative care
-
NCT06549075Not yet recruitingPromoting Dignity, Meaningfulness and Mindfulness in Acute Palliative Care
-
NCT07469761RecruitingCancer | Frailty | Palliative Care | Outpatient | Palliative Care, Health Services | Patient Reported Outcome Measurements | Patient Reported Outcome (PRO)
-
NCT05237258RecruitingHigh Risk Acute Myeloid Leukemia | Relapsed Adult AML | Primary Refractory Acute Myeloid Leukemia
-
NCT03375489Completed
-
NCT02139917CompletedPalliative Care | Renal Failure, End-stage
-
NCT01589601CompletedHeart Diseases | Cardiovascular Diseases | Heart Failure
-
NCT02786524CompletedUterine Cervical Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Vulvar Neoplasms | Vaginal Neoplasms | Gynecologic Neoplasms